MDLN · Medline Inc.
Key customers — 74% of revenue (the year ended December 31, 2025)
“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”
Key customers — 69% of revenue (the year ended December 31, 2025)
“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”
5 customers — 11.3% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, our top five U.S. customers represented approximately $3.2 billion (or 11.3%) of our net sales.”
Price & Indicators
The closing range uses available history since Dec 17, 2025; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Medline raised full-year organic sales guidance to 9.0%–10.0% on 11.6% Q2 net sales growth and $650M of new customer signings, while cutting full-year adjusted EBITDA guidance to $3.3–$3.4B from $3.5–$3.6B and absorbing a $336M Tracy fire loss that pushed GAAP net income down 58.3%.
- + Q2 net sales rose 11.6% to $7.7 billion
- + Achieved over 65% of $1B annual signings goal with $650M in H1 new wins
- + Q2 Adjusted EBITDA grew 13.4% to $1.06B including $243M net IEEPA tariff refund benefit
- + Supply chain solutions grew 16% to $4.1B driven by new signings and existing customer growth
- − Cut full-year adjusted EBITDA guidance to $3.3–$3.4B from $3.5–$3.6B
- − Tracy fire drove $336M Q2 loss before insurance recoveries, reducing GAAP net income 58.3%
- − Expect additional $50–$100M of Tracy-related costs in H2 2026
- − Retail channel softness expected to remain a headwind for the balance of the year
- − Quality remediation delays product reintroductions, including CHG wipes, causing earnings loss
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDLN
this stock
Medline Inc.
|
$45.62B | -16.7% | +11.5% | — | 3.1% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -27.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
RMD
Resmed Inc
|
$32.02B | -7.5% | +13.4% | 21.3 | 9.8% |
|
ALC
Alcon Inc
|
$31.52B | -17.0% | +10.5% | — | 3.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDLN | +1.6% | -0.1% | -21.1% | -0.1% | -16.7% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | +2.8% | +0.2% | -34.2% | +0.2% | -28.8% |